JPRN-UMIN000011971已完成2 期
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib in Japan adult leukemia study group study - JALSG-STIM213 Study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 62
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patients with a history of treatment by the other TKI. 2)Patients with a history of hematopoietic stem cell transplantation. 3)Patients who have had blast crisis or accelerated CML. 4) Patients who have lost CMR during imatinib treatment. 5)Patients who have discontined imatinib treatment because of poor adherence. 6)Patients who do not want to re start imatinib after lost of MMR. 7)Other patients whom the investigator considers to be unsuitable for participation in the study.
研究者
相似试验
进行中（未招募）
1 期
Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor that has become radiologically undetectable with treatmentGastrointestinal stromal tumour (GIST)MedDRA version: 20.0Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003774-40-FIOslo University Hospital31
招募中
2 期
Imatinib discontinuation for Chronic Myelogenou Leukemia-Chronic Phase with 2 years complete molecular remission.Chronic Myelogenou Leukemia-Chronic Phase who have maintained complete molecular remission for at least 2 years.JPRN-UMIN000012472Epidemiological and Clinical Research Information Network (ECRIN)100
尚未招募
不适用
To stop the use of Imatinib in CML-CP patientsCTRI/2019/07/020407DR BRA IRCH AIIMS
已完成
2 期
Discontinuation study of nilotinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter stop study in Japan adult leukemia study groupchronic myeloid leukemiaJPRN-UMIN000024985Japan Adult Leukemia Study Group51
已完成
2 期
Discontinuation study of nilotinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter stop study in Japan adult leukemia study groupchronic myeloid leukemiaJPRN-UMIN000024984Japan Adult Leukemia Study Group51